KTN's online platform helps you to make the connections you need


The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.


The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the release of their 2015 Annual Review. The link to the annual review can be found here: https://ct.catapult.org.uk/annual-review

The second review covers the 12 months from April 2014 to 2015, during which the Cell Therapy Catapult reached all key milestones and delivered a number of high quality projects. These achievements include:

Rapidly growing a project portfolio – In November 2014 the first clinical trial run by the Cell Therapy Catapult commenced with the first patient receiving an experimental T-cell therapy. In addition, the Cell Therapy Catapult launched 20 new project collaborations addressing cell, and gene modified cell therapies and their underlying technologies. These involved 30 different UK and international partners, attracting funding totalling £17.3 million. 45 smaller projects to assist clients’ product development and technologies were also executed.

Building infrastructure – The UK government’s Secretary of State for Business Innovation and Skills opened the Cell Therapy Catapult headquarters at the Tower Wing of Guy’s Hospital in London in June 2014. The headquarters include 1,200m2 of state-of-the-art development laboratories. The Cell Therapy Catapult also completed the venue selection process for its £55 million, 7,200m2 world-leading, large-scale GMP manufacturing centre. The venue selected was the Stevenage Bioscience Catalyst. The centre is scheduled to open in 2017.

Growing cell and gene therapy expertise – The Cell Therapy Catapult hired its 100th professional in a team now covering an entire range of skills from clinical and process development to healthcare economics.

Influencing – The Cell Therapy Catapult played a key role in the UK’s Regenerative Medicine Expert Group with a focus on regulation, manufacturing, clinical delivery and reimbursement. The UK government accepted all key recommendations and these are being progressed. The annually refreshed clinical, preclinical and manufacturing databases developed by the Cell Therapy Catapult are now an important resource for the industry. The Cell Therapy Catapult continues to put the UK at the centre of attention in advanced therapies hosting 81 delegations ranging from government officials, academics and industry from the UK and internationally.

“The Cell Therapy Catapult second annual review highlights a high number of key achievements across a variety of areas that will have a direct impact upon both health and the economy in the UK,” said Keith Thompson, CEO, the Cell Therapy Catapult. “Supported by Innovate UK, we have enhanced the Cell Therapy Catapult in its second year from a fledgling organisation to one capable of tackling scientific, technical, clinical, regulatory and business barriers to the development of the industry. We will continue to benchmark our achievements and successes against the impact on creation and expansion of the cell and gene therapy industry and, of course, on patients’ lives.”